Grant: Idea to Innovation
University of Toronto
$125,000.00
I2I phase I: assessment of genotypic markers for profiling of circulating tumor cells
EF 2018-19
Résumé
Current cancer staging methods are not broadly effective when applied to predicting tumor prognosis and response to therapy, driving the need for specific tumor characterization approaches. Two aspects which confound the ability to predict tumor prognosis and assign appropriate therapies are the heterogeneous nature of cancers and the difficulty of identifying metastases in a timely manner. A promising approach that may serve to address these problems is the analysis of Circulating Tumour Cells (CTCs). As the CTCs are shed from the primary tumour itself, these rare cells can provide a means to re-characterize a tumour during treatment without the need for continual re-biopsy. This can be particularly powerful when assessing CTC phenotype to understand disease aggressiveness, or CTC genotyping for applications in precision medicine. To this date, technologies being developed for CTCs focus on capture and enumeration of these rare cells and rely on off-chip assays for assessment of CTC population phenotypes and genotypes. Thus, a single solution is not available for characterization of CTCs within a patient's blood sample with the goal of developing a ""liquid biopsy"" to inform treatment decisions. *In response to a need for technology to simultaneously capture and molecularly characterize a CTC population, we have developed a new technology - Magnetic Ranking Cytometry (MagRC) - that enables CTC profiling at the level of protein and mRNA expression. This approach uses a new type of microfluidic device that sorts the cells into different capture zones according to the number of nanoparticles bound, and can measure expression levels calculated by the location of the cells within the device. The proposed project aims to rigorously validate this technology, assess manufacturability of assay consumables, and develop the necessary companion technologies for assay automation. *
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
530366-2018
Name nom
Kelley, Shana
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
I2I phase I: assessment of genotypic markers for profiling of circulating tumor cells
Keyword
NSERC
Application summary
Current cancer staging methods are not broadly effective when applied to predicting tumor prognosis and response to therapy, driving the need for specific tumor characterization approaches. Two aspects which confound the ability to predict tumor prognosis and assign appropriate therapies are the heterogeneous nature of cancers and the difficulty of identifying metastases in a timely manner. A promising approach that may serve to address these problems is the analysis of Circulating Tumour Cells (CTCs). As the CTCs are shed from the primary tumour itself, these rare cells can provide a means to re-characterize a tumour during treatment without the need for continual re-biopsy. This can be particularly powerful when assessing CTC phenotype to understand disease aggressiveness, or CTC genotyping for applications in precision medicine. To this date, technologies being developed for CTCs focus on capture and enumeration of these rare cells and rely on off-chip assays for assessment of CTC population phenotypes and genotypes. Thus, a single solution is not available for characterization of CTCs within a patient's blood sample with the goal of developing a ""liquid biopsy"" to inform treatment decisions. *In response to a need for technology to simultaneously capture and molecularly characterize a CTC population, we have developed a new technology - Magnetic Ranking Cytometry (MagRC) - that enables CTC profiling at the level of protein and mRNA expression. This approach uses a new type of microfluidic device that sorts the cells into different capture zones according to the number of nanoparticles bound, and can measure expression levels calculated by the location of the cells within the device. The proposed project aims to rigorously validate this technology, assess manufacturability of assay consumables, and develop the necessary companion technologies for assay automation. *